|Hospital:||St. Bartholomew’s Hospital|
|Patients: This Phase II study involved 29 patients with malignant pleural mesothelioma. None of these patients had been administered previous chemotherapy or immunotherapy.|
Treatment: The treatment consisted of the administration of human recombinant Interleukin-2.
Toxicity: Toxicities included fever (grade 2), cutaneous toxicity, nausea and vomiting (grade 1), and chest pains.
Results: Overall median survival was 9 months from the date of first treatment.
Support: The cost of the interleukin-2 was subsidized by Chiron UK Limited. Chiron manufactures interleukin-2 (Proleukin).
Correspondence: R.M. Rudd, MD